系统性硬化症 (BASICS) 患者的BAricitinib:一个前性的,开放标签的,随机化试验
Fangfang Chen1,2,3, Wenjing Ye1,2,3, Qian Wang1,2,3
1Department of Rheumatology, Huashan Hospital, Institute of Rheumatology, Immunology and Allergy, Fudan University, No. 12, Middle Urumqi Road, Jing'an District, Shanghai, 200000, China.
Clinical rheumatology
|May 17, 2025
概括
巴里西替尼4毫克改善了系统性硬化症 (SSc) 患者的皮肤评分,这表明它在免疫炎症中起作用. 这项研究支持进一步研究用于SSc治疗的Janus激酶 (JAK) 抑制剂.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性硬化症 (SSc) 治疗的进步取得了适度的结果.
- 巴里西提尼布是一种简氏激酶 (JAK) 抑制剂,具有潜在的治疗益处.
研究的目的:
- 评估巴里西提尼布在SSc患者中的治疗益处和安全性.
- 探索影响巴里西提尼布在SSc.疗效的遗传因素.
主要方法:
- 一项为期24周的随机研究,比较巴里西提尼布 (4毫克,2毫克) 与对照组.
- 主要结局:12周后修改的罗丹皮肤评分 (mRSS) 的变化.
- 二级结局包括ACR-CRISS,FVC,数字,EQ5D和安全性;进行了转录组分析.
主要成果:
- 巴里西提尼布4毫克在12周后显著改善了mRSS (P=0.019).
- 在FVC,手指和EQ5D中,在24周内使用4毫克巴里西提尼布观察到有利的反应.
- 基因本体学分析显示,免疫反应途径的丰富;IL-1RL1和SYT17基因表达被改变.
结论:
- 巴里西提尼布4毫克在SSc患者中显示出临床改善,具有可接受的安全性.
- 该机制可能涉及影响免疫炎症途径.
- 需要进一步调查SSc的巴里西提尼布对JAK 1/2抑制的研究.
相关概念视频
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K


